Challenges in the treatment of Rheumatoid Arthritis

Autoimmunity Reviews

Volumn 18, Issue 7, 2019, Pages 706-713

  Conigliaro, Paola ^a   Triggianese, Paola ^a   De Martino, Erica ^a   Fonti, Giulia Lavinia ^a   Chimenti, Maria Sole ^a   Sunzini, Flavia ^a   Viola, Alessandra ^a   Canofari, Claudia ^a   Perricone, Roberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

bDMARDs; Comorbidities; Diet; Extra articular manifestations; HLA; Physical activity; Pregnancy; Rheumatoid Arthritis

Indexed keywords

CIGARETTE SMOKE; DECERNOTINIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FILGOTINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DRB1 ANTIGEN; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; MICRORNA 146A; PROTEIN; PSORS1C1 PROTEIN; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG; UPADACITINIB; ANTIRHEUMATIC AGENT;

AUTOIMMUNE DISEASE; CACAO; CLINICAL OUTCOME; COMORBIDITY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL FACTOR; GENETIC PROFILE; HUMAN; INFLAMMATORY DISEASE; MEDITERRANEAN DIET; OBESE PATIENT; OBESITY; PHYSICAL ACTIVITY; PREGNANCY; REVIEW; RHEUMATOID ARTHRITIS; SALT INTAKE; ANIMAL;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS;

EID: 85065136485     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2019.05.007     Document Type: Review

References (142)

1. Raychaudhuri, S., et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 41 (2009), 1313–1318.
2. Gregersen, P.K., Silver, J., Winchester, R.J., The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30 (1987), 1205–1213.
3. Viatte, S., Barton, A., The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease. Eur Musculoskelet Rev 7:2 (2012), 102–107.
4. Viatte, S., Plant, D., Han, B., et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA 313 (2015), 1645–1656.
5. Ling, S.F., Viatte, S., Lunt, M., et al. HLA-DRB1 amino acid positions 11/13, 71, and 74 are associated with inflammation level, disease activity, and the health assessment questionnaire score in patients with inflammatory polyarthritis. Arthritis Rheumatol 68 (2016), 2618–2628.
6. de Rooy, D.P., Tsonaka, R., Andersson, M.L., et al. Genetic factors for the severity ofACPA-negative rheumatoid arthritis in 2 cohorts of early disease: a genome-wide study. J Rheumatol 42 (2015), 1383–1391.
7. Ciccacci, C., Conigliaro, P., Perricone, C., et al. Polymorphisms in STAT-4, IL-10, PSORS1C1,PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis. Clin Exp Immunol 186 (2016), 157–163.
8. Viatte, S., Barton, A., Genetics of rheumatoid arthritis susceptibility, severity,and treatment response. Semin Immunopathol 39 (2017), 395–408.
9. Bottini, N., Firestein, G.S., Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol 9 (2013), 24–33.
10. Nakano, K., Whitaker, J.W., Boyle, D.L., et al. DNA methylome signature of rheumatoid arthritis synoviocytes. Ann Rheum Dis 72 (2013), 110–117.
11. Conigliaro, P., Ciccacci, C., Politi, C., et al. Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 genes are associated with the response to tnf inhibitors in patients with rheumatoid arthritis. PLoS One, 12(1), 2017, e0169956.
12. Sieberts, S.K., et al. Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun, 7, 2013, 12460.
13. Castro-Villegas, C., Pérez-Sánchez, C., Escudero, A., et al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Arthritis Res Ther, 17, 2015, 49.
14. Wijbrandts, C.A., Tak, P.P., Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin Proc 92:7 (2017), 1129–1143.
15. Chimenti, M.S., Triggianese, P., Conigliaro, P., et al. A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors. Clin Rheumatol 36:10 (2017), 2253–2260.
16. Roodenrijs, N.M.T., de Hair, M.J.H., van der Goes, M.C., et al. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis 77 (2018), 1705–1709.
17. Conigliaro, P., Chimenti, M.S., Triggianese, P., et al. Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor. J Int Med Res 44 (2016), 90–94.
18. Conigliaro, P., Triggianese, P., Chimenti, M.S., et al. Factors predicting 2 years of remission and low disease activity in rheumatoid arthritis patients treated with TNF-inhibitors. Isr Med Assoc J 19:8 (2017), 467–472.
19. Bazzichi, L., Rossi, P., Giacomelli, C., et al. A proposal of simple calculation (ERI calculator) to predict the early response to TNF-α blockers therapy in rheumatoid arthritis. Rheumatol Int 32:2 (2012), 349–356.
20. Meugnier, E., Coury, F., Tebib, J., et al. Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-alpha treatments. Physiol Genomics 43 (2011), 365–371.
21. Ranganath, V.K., Maranian, P., Elashoff, D.A., et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford) 52:10 (2013), 1809–1817.
22. Cojocaru, M., Cojocaru, I.M., Silosi, I., et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Buchar) 5:4 (2010), 286–291.
23. Arranz, L.I., Rafecas, M., Alegre, C., Effects of obesity on function and quality of life in chronic pain conditions. Curr Rheumatol Rep, 16(1), 2014, 390.
24. Goossens, J., Coustet, B., Palazzo, E., et al. Overweight and obesity affect clinical assessment of synovitis in rheumatoid arthritis: comparison of ultrasonography and clinical exam. Clin Exp Rheumatol 37 (2019), 49–54.
25. Daïen, I.C., Sellam, J., Obesity and inflammatory arthritis: impact on occurrence, disease characteristics and therapeutic response. RMD Open, 29, 2015 [1(1)].
26. Gremese, E., Carletto, A., Padovan, M., et al. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) 65:1 (2013), 94–100.
27. D'Agostino, M.A., Alten, R., Mysler, E., et al. Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. Clin Rheumatol 36:12 (2017), 2655–2665.
28. Iannone, F., Courvoisier, D.S., Gottenberg, J.E., et al. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the pan-European registry collaboration for abatacept (PANABA). Clin Rheumatol 36:4 (2017), 773–779.
29. Gardette, A., Ottaviani, S., Sellam, J., et al. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clin Rheumatol 35:4 (2016), 857–861.
30. Skeoch, S., Bruce, I.N., Atherosclerosis in rheumatoid arthritis: is it all about inflammation?. Nat Rev Rheumatol 11:7 (2015), 390–400.
31. Dougados, M., Soubrier, M., Antunez, A., et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:1 (2014), 62–68.
32. Galloway, J.B., Hyrich, K.L., Mercer, L.K., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology biologics register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50:1 (2011), 124–131.
33. Ballanti, E., Conigliaro, P., Chimenti, M.S., et al. Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. Drug Dev Res 75:Suppl. 1 (2014), S42–S45.
34. Conigliaro, P., Chimenti, M.S., Ascolani, M., et al. Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. Autoimmun Rev 15:2 (2016), 184–190.
35. Romano, S., Salustri, E., Ruscitti, P., et al. Cardiovascular and metabolic comorbidities in rheumatoid arthritis. Curr Rheumatol Rep, 20(12), 2018, 81.
36. Gardette, A., Ottaviani, S., Sellam, J., et al. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clin Rheumatol 35:4 (2016), 857–861.
37. Voskuyl, A.E., Zwinderman, A.H., Westedt, M.L., et al. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis 55 (1996), 190–192.
38. Turesson, C., Jacobsson, L., Bergström, U., et al. Predictors of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 29 (2000), 358–364.
39. Weyand, C.M., Xie, C., Goronzy, J.J., Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. J Clin Invest 89 (1992), 2033–2039.
40. Turesson, C., Jacobsson, L.T., Sturfelt, G., et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 66:1 (2007), 59–64.
41. Makol, A., Crowson, C.S., Wetter, D.A., et al. Vasculitis associated with rheumatoid arthrtis: a case-control study. Rheumatology (Oxford) 53:5 (2014), 890–899.
42. Sokumbi, O., Wetter, D.A., Makol, A., et al. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc 87:8 (2012), 739–745.
43. Das, S., Padhan, P., An overview of the Extraarticular involvement in rheumatoid arthritis and its management. J Pharmacol Pharmacother 8:3 (2017), 81–86.
44. Iqbal, K., Kelly, C., Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis 7:6 (2015), 247–267.
45. Druce, K.L., Iqbal, K., Watson, K.D., et al. Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic. RMD Open, 3(1), 2017, e000473.
46. Andreoli, L., Lazzaroni, M.G., Carini, C., et al. “Disease knowledge index” and perspectives on reproductive issues: a nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine 10:18 (2018), 30257–30264.
47. Andreoli, L., Gerardi, M.C., Fernandes, M., et al. Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. Autoimmun Rev 18:2 (2019), 164–176.
48. Perricone, C., de Carolis, C., Perricone, R., Pregnancy and autoimmunity: a common problem. Best Pract Res Clin Rheumatol 26:1 (2012), 47–60.
49. Østensen, M., Andreoli, L., Brucato, A., et al. State of the art: reproduction and pregnancy in rheumatic diseases. Autoimmun Rev 14:5 (2015), 376–386.
50. Jethwa, H., Lam, S., Smith, C., et al. Does rheumatoid arthritis really improve during pregnancy? A systematic review and Metaanalysis. J Rheumatol, 2018, 180–226.
51. de Man, Y.A., Dolhain, R.J., Van de Geijn, F.E., et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 59 (2008), 1241–1248.
52. Skomsvoll JF, Ostensen M, Irgens LM, et al. Perinatal outcome in pregnancies of women with connective tissue disease and inflammatory rheumatic disease in Norway. Scand J Rheumatol 999;28:352–356.
53. Wolfberg, A.J., Lee-Parritz, A., Peller, A.J., et al. Association of rheumatologic disease with preeclampsia. Obstet Gynecol 103:6 (2004), 1190–1193.
54. Ong, K.K., Dunger, D.B., Perinatal growth failure: the road to obesity, insulin resistance and cardiovascular rdisease in adults. Best Pract Res Clin Endocrinol Metab 16 (2002), 191–207.
55. Leunissen, R.W., Kerkhof, G.F., Stijnen, T., et al. Timing and temp of first-year rapid growth in relation of cardiovascular and metabolic risk profile in early adulthood. JAMA 301 (2009), 2234–2242.
56. de Man, Y.A., Bakker-Jonges, L.E., Goorbergh, C.M., et al. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy. Ann Rheum Dis 69:2 (2010), 420–423.
57. Nelson, J.L., Hansen, J.A., Autoimmune diseases and HLA. Crit Rev Immunol 10:4 (1990), 307–328.
58. van der Horst-Bruinsma, I.E., de Vries, R.R., de Buck, P.D., et al. Influence of HLA-class II incompatibility between mother and fetus on the development and course of rheumatoid arthritis of the mother. Ann Rheum Dis 57 (1998), 286–290.
59. Zrour, S.H., Boumiza, R., Sakly, N., et al. The impact of pregnancy on rheumatoid arthritis outcome: the role of materno fetal HLA class II disparity. Jt Bone Spine 77 (2010), 36–40.
60. Capellino, S., Straub, R.H., Cutolo, M., Aromatase and regulation of the estrogen-to androgen ratio in synovial tissue inflammation: common pathway in both sexes. Ann N Y Acad Sci 1317 (2014), 24–31.
61. Capellino, S., Montagna, P., Villaggio, B., et al. Hydroxylated estrogen metabolites influence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. Clin Exp Rheumatol 26:5 (2008), 903–909.
62. van den Broe, N.R., Letsky, E.A., Pregnancy and the erythrocyte sedimentation rate. BJOG 108:11 (2001), 1164–1167.
63. de Man, Y.A., Hazes, J.M., van de Geijn, F.E., et al. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum 57:5 (2007), 716–722 15.
64. Østensen, M., Khamashta, M., Lockshin, M., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther, 8(3), 2006, 209.
65. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 016;75(5):795–810.
66. Bermas, B.L., Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Curr Opin Rheumatol 26:3 (2014), 334–340.
67. Østensen, M., Khamashta, M., Lockshin, M., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther, 8(3), 2006, 209.
68. Weber-Schoendorfer, C., Beck, E., Tissen-Diabaté, T., et al. Leflunomide – a human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. Reprod Toxicol 71 (2017), 101–107.
69. Weber-Schoendorfer, C., Chambers, C., Wacker, E., et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol 66:5 (2014), 1101–1110.
70. Hyrich, K.L., Verstappen, S.M., Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford) 53:8 (2014), 1377–1385.
71. Chaudrey, K.H., Kane, S.V., Safety of Immunomodulators and anti-TNF therapy in pregnancy. Curr Treat Options Gastroenterol 13:1 (2015), 77–89.
72. Weber-Schoendorfer, C., Schaefer, C., Pregnancy outcome after tocilizumab therapy in early pregnancy-a case series from the German Embryotox Pharmacovigilance Center. Reprod Toxicol 60 (2016), 29–32.
73. Clowse, M.E., Feldman, S.R., Isaacs, J.D., et al. Pregnancy outcomes in the Tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf 39:8 (2016), 755–762.
74. Gerosa, M., Argolini, L.M., Artusi, C., et al. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol 11:10 (2018), 987–998.
75. Smolen, J.S., Landewé, R., Bijlsma, J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:6 (2017), 960–977.
76. Venkatesha, S.H., Dudics, S., Acharya, B., et al. Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci 16:1 (2014), 887–906.
77. Fleischmann, R., Kremer, J., Cush, J., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:6 (2012), 495–507.
78. van der Heijde, D., Tanaka, Y., Fleischmann, R., et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:3 (2013), 559–570.
79. Fleischmann, R., Mysler, E., Hall, S., et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase IIIb/IV, double-blind, head-to-head, randomised controlled trial. Lancet 390:10093 (2017), 457–546.
80. Kunwar, S., Collins, C.E., Constantinescu, F., Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clin Rheumatol 37 (2018 Jul 13), 2611–2620.
81. Hamilton, J.A., Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8 (2008), 533–544.
82. Fleetwood, A.J., Cook, A.D., Hamilton, J.A., Functions of granulocyte-macrophage colony- stimulating factor. Crit Rev Immunol 25 (2005), 405–428.
83. Behrens, F., Tak, P.P., Ostergaard, M., et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 74 (2015), 1058–1064.
84. Molfino, N.A., Kuna, P., Leff, J.A., et al. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM- CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open, 6, 2016 e007709.
85. Huizinga, T.W., Batalov, A., Stoilov, R., et al. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Res Ther, 19, 2017, 53.
86. Burmester, G.R., Weinblatt, M.E., McInnes, I.B., et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 72 (2013), 1445–1452.
87. Guo, X., Higgs, B.W., Bay-Jensen, A.C., et al. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis. Rheumatology (Oxford) 57:1 (2018), 175–184.
88. Burmester, G.R., Lin, Y., Patel, R., et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76:5 (2017), 840–847.
89. Aletaha, D., Bingham, C.O. 3rd, Tanaka, Y., et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet 389:10075 (2017), 1206–1217.
90. Gossage, D.L., Cieslarová, B., Ap, S., et al. Phase 1b study of the safety, pharmacokinetics, and disease-related outcomes of the matrix Metalloproteinase-9 inhibitor Andecaliximab in patients with rheumatoid arthritis. Clin Ther 40:1 (2018), 156–165.e5.
91. Tanaka, Y., Takeuchi, T., Umehara, H., et al. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Mod Rheumatol 28:1 (2018), 58–65.
92. Moschovakis, G.L., Bubke, A., Friedrichsen, M., et al. The chemokine receptor CCR7 is a promising target for rheumatoid arthritis therapy. Cell Mol Immunol, 2018 Jul 4, 10.1038/s41423-018-0056-5.
93. Vanhoutte, F., Mazur, M., Voloshyn, O., et al. Efficacy, safety, pharmacokinetics, and pharmacodynamics of Filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase IIa trials. Arthritis Rheumatol 69:10 (2017), 1949–1959.
94. Kremer, J.M., Emery, P., Camp, H.S., et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol 68:12 (2016), 2867–2877.
95. Genovese, M.C., Smolen, J.S., Weinblatt, M.E., et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol 68:12 (2016), 2857–2866.
96. Genovese, M.C., Greenwald, M., Codding, C., et al. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying Antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol 69:5 (2017), 932–942.
97. Genovese, M.C., van Vollenhoven, R.F., Pacheco-Tena, C., et al. VX-509 (Decernotinib), an Oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 68:1 (2016), 46–55.
98. Fleischmann, R.M., Damjanov, N.S., Kivitz, A.J., et al. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol 67:2 (2015), 334–343.
99. Iris, M., Tsou, P.S., Sawalha, A.H., Caffeine inhibits STAT1 signaling and downregulates inflammatory pathways involved in autoimmunity. Clin Immunol 192 (2018), 68–77.
100. Forsyth, C., Kouvari, M., D'Cunha, N.M., et al. The effects of the Mediterranean diet on rheumatoid arthritis prevention and treatment: a systematic review of human prospective studies. Rheumatol Int 38:5 (2018), 737–747.
101. Khanna, S., Jaiswal, K.S., Gupta, B., Managing rheumatoid arthritis with dietary interventions. Front Nutr, 4, 2017, 52.
102. Philippou, E., Nikiphorou, E., Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis. Autoimmun Rev 17:11 (2018), 1074–1077.
103. Petersson, S., Philippou, E., Rodomar, C., et al. The Mediterranean diet, fish oil supplements and rheumatoid arthritis outcomes: evidence from clinical trials. Autoimmun Rev 17:11 (2018), 1105–1114.
104. Sköldstam, L., Hagfors, L., Johansson, G., An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis 62:3 (2003), 208–214.
105. Rosillo, M.A., Sánchez-Hidalgo, M., Sánchez-Fidalgo, S., et al. Dietary extra-virgin olive oil prevents inflammatory response and cartilage matrix degradation in murine collagen-induced arthritis. Eur J Nutr 55:1 (2016), 315–325.
106. Rambod, M., Nazarinia, M., Raieskarimian, F., The impact of dietary habits on the pathogenesis of rheumatoid arthritis: a case-control study. Clin Rheumatol 37:10 (2018), 2643–2648.
107. Lourdudoss, C., Di Giuseppe, D., Wolk, A., et al. Dietary intake of polyunsaturated fatty acids and pain in spite of inflammatory control among methotrexate-treated early rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 70:2 (2018), 205–212.
108. Sharif, K., Amital, H., Shoenfeld, Y., The role of dietary sodium in autoimmune diseases: the salty truth. Autoimmun Rev 17:11 (2018), 1069–1073.
109. Marouen, S., du Cailar, G., Audo, R., et al. Sodium excretion is higher in patients with rheumatoid arthritis than in matched controls. PLoS One, 12(10), 2017, e0186157.
110. Sigaux, J., Semerano, L., Favre, G., et al. Salt, inflammatory joint disease, and autoimmunity. Joint Bone Spine 85:4 (2018), 411–416.
111. Ip, W.K., Medzhitov, R., Macrophages monitor tissue osmolarity and induce inflammatory response through NLRP3 and NLRC4 inflammasome activation. Nat Commun, 6, 2015 May 11, 6931.
112. Sundström, B., Johansson, I., Rantapää-Dahlqvist, S., Interaction between dietary sodium and smoking increases the risk for rheumatoid arthritis: results from a nested case-control study. Rheumatology (Oxford) 54:3 (2015), 487–493.
113. Binger, K.J., Gebhardt, M., Heinig, M., et al. High salt reduces the activation of IL-4- and IL-13-stimulated macrophages. J Clin Invest 125:11 (2015), 4223–4238.
114. Scrivo, R., Massaro, L., Barbati, C., et al. The role of dietary sodium intake on the modulation of T helper 17 cells and regulatory T cells in patients with rheumatoid arthritis and systemic lupus erythematosus. PLoS One, 12(9), 2017, e0184449.
115. Horrigan, L.A., Kelly, J.P., Connor, T.J., Immunomodulatory effects of caffeine: friend or foe?. Pharmacol Ther 111:3 (2006), 877–892.
116. Al Reef, T., Ghanem, E., Caffeine: well-known as psychotropic substance, but little as immunomodulator. Immunobiology 223:12 (2018), 818–825.
117. Karlson, W.E., Mandl, L.A., Aweh, G.N., et al. Coffee consumption and risk of rheumatoid arthritis. Arthritis Rheum, 2003, 3055–3060.
118. Lee, Y.H., Bae, S.C., Song, G.G., Coffee or tea consumption and the risk of rheumatoid arthritis: a meta-analysis. Clin Rheumatol 33:11 (2014), 1575–1583.
119. Pérez-Cano, Francisco J., Massot-Cladera, Malen, et al. The effects of cocoa on the immune system. Front Pharmacol, 4, 2013, 71.
120. Camps-Bossacoma, M., Massot-Cladera, M., Abril-Gil, M., et al. Cocoa diet and antibody immune response in preclinical studies. Front Nutr, 4, 2017, 28.
121. Ramos-Romero, S., Pérez-Cano, F.J., Ramiro-Puig, E., et al. Cocoa intake attenuates oxidative stress associated with rat adjuvant arthritis. Pharmacol Res 66:3 (2012), 207–212.
122. Ramos-Romero, S., Pérez-Cano, F.J., Pérez-Berezo, T., et al. Effect of a cocoa flavonoid-enriched diet on experimental autoimmune arthritis. Br J Nutr 107:4 (2012), 523–532.
123. He, Y., Yue, Y., Zheng, X., et al. Review Curcumin, inflammation, and chronic diseases: how are they linked?. Molecules 20:5 (2015), 9183–9213.
124. Shen, L., Liu, C.C., An, C.Y., Ji, H.F., et al. How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies. Sci Rep, 6, 2016, 20872.
125. Daily, J.W., Yang, M., Park, S., Efficacy of turmeric extracts and Curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. J Med Food 19:8 (2016), 717–729.
126. Zheng, Z., Sun, Y., Liu, Z., et al. The effect of curcumin and its nanoformulation on adjuvant-induced arthritis in rats. Drug Des Devel Ther 9 (2015), 4931–4942.
127. Dragos, D., Gilca, M., Gaman, L., et al. Phytomedicine in joint disorders. Nutrients., 9(1), 2017, 70.
128. Klareskog, L., Stolt, P., Lundberg, K., et al. A new model for an Etiology of rheumatoid arthritis. Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by Citrullination. Arthritis Rheum 54:1 (2006), 38–46.
129. Chang, K., So, Min Yang, Kim, Seong Heon, et al. Smoking and rheumatoid arthritis. Int J Mol Sci 15:12 (2014), 22279–22295.
130. Finckh, A., Dehler, S., Costenbader, K.H., et al. Cigarette smoking and radiographic progression in rheumatoid arthritis. Ann Rheum Dis 66:8 (2007), 1066–1071.
131. Rydell, E., Forslind, K., Nilsson, J.A., et al. Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis. Arthritis Res Ther, 20, 2018, 82.
132. Abhishek, A., Butt, S., Gadsby, K., et al. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol 16 (2010), 15–18.
133. Chatzidionysiou, K., Lukina, G., Gabay, C., et al. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration. Scand J Rheumatol, 2018, 1–7.
134. Conigliaro, P., Triggianese, P., Ippolito, F., et al. Insights on the role of physical activity in patients with rheumatoid arthritis. Drug Dev Res 75:Suppl. 1 (2014), S54–S56.
135. Chimenti, M.S., Triggianese, P., Conigliaro, P., et al. Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity. Drug Dev Res 75:Suppl. 1 (2014), S57–S59.
136. Steensberg, A., Toft, A.D., Bruunsgaard, H., et al. Strenuous exercise decreases the percentage of type 1 T cells in the circulation. J Appl Physiol (1985) 91:4 (2001), 1708–1712.
137. Rochette, E., Duché, P., Merlin, E., Juvenile idiopathic arthritis and physical activity: possible inflammatory and immune modulation and tracks for interventions in young populations. Autoimmun Rev 14:8 (2015), 726–734.
138. Baillet, A., Zeboulon, N., Gossec, L., et al. Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 62:7 (2010), 984–992.
139. Sharif, K., Watad, A., Bragazzi, N.L., et al. Physical activity and autoimmune diseases: get moving and manage the disease. Autoimmun Rev 17:1 (2018), 53–72.
140. Curtis, G.L., Chughtai, M., Khlopas, A., et al. Impact of physical activity in cardiovascular and musculoskeletal health: can motion be medicine?. J Clin Med Res 9:5 (2017), 375–381.
141. Rausch Osthoff, A.K., Niedermann, K., Braun, J., et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis 77:9 (2018), 1251–1260.
142. Geenen, R., Overman, C.L., Christensen, R., et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis 77 (2018), 797–807.